Cover Image
市場調查報告書

粒腺體病:開發平台分析

Mitochondrial Diseases - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 293893
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
粒腺體病:開發平台分析 Mitochondrial Diseases - Pipeline Review, H1 2014
出版日期: 2014年05月30日 內容資訊: 英文 50 Pages
簡介

所謂的粒腺體病是除了紅血球以外所有細胞內的粒腺體異常引起的疾病, 是因mtDNA或nDNA的遺傳性變異或自然突變,造成一般粒腺體的蛋白質或RNA分子功能低落。其症狀有發育遲緩、痴呆、全身無力、痙攣、大腸躁鬱症、肌痛、腹瀉、便秘等。

本報告網羅全球粒腺體病治療藥的開發平台相關資料,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

粒腺體病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

粒腺體病:開發中的治療藥:各企業

粒腺體病:開發中的治療藥:大學·研究機關別

粒腺體病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

粒腺體病:開發中的產品:各企業

粒腺體病:開發中的產品:大學·研究機關別

粒腺體病:治療藥開發作的企業

  • NeuroVive Pharmaceutical AB
  • Edison Pharmaceuticals, Inc.
  • ElexoPharm GmbH

粒腺體病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • vatiquinone
  • OT-15
  • MTP-131
  • NVP-015
  • Alkylaminoquinone Based Multifunctional Radical Quenchers
  • Eurostars Program
  • 粒腺體病藥物
  • 以細胞能量代謝作為標的藥物
  • 粒腺體病小分子
    • 產品概要
    • 作用機制
    • R&D的進展

粒腺體病:最近的開發平台趨勢

粒腺體病:暫停中的計劃

粒腺體病:中止計劃

粒腺體病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5051IDB

Global Markets Direct's, 'Mitochondrial Diseases - Pipeline Review, H1 2014', provides an overview of the Mitochondrial Diseases's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mitochondrial Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mitochondrial Diseases and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mitochondrial Diseases
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mitochondrial Diseases and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mitochondrial Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mitochondrial Diseases pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mitochondrial Diseases
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mitochondrial Diseases pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mitochondrial Diseases Overview
  • Therapeutics Development
    • Pipeline Products for Mitochondrial Diseases - Overview
    • Pipeline Products for Mitochondrial Diseases - Comparative Analysis
  • Mitochondrial Diseases - Therapeutics under Development by Companies
  • Mitochondrial Diseases - Therapeutics under Investigation by Universities/Institutes
  • Mitochondrial Diseases - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Mitochondrial Diseases - Products under Development by Companies
  • Mitochondrial Diseases - Products under Investigation by Universities/Institutes
  • Mitochondrial Diseases - Companies Involved in Therapeutics Development
    • NeuroVive Pharmaceutical AB
    • Edison Pharmaceuticals, Inc.
    • ElexoPharm GmbH
  • Mitochondrial Diseases - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OT-15 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTP-131 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-015 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alkylaminoquinone Based Multifunctional Radical Quenchers - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Eurostars Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Mitochondrial Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs Targeting Cellular Energy Metabolism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Mitochondrial Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mitochondrial Diseases - Recent Pipeline Updates
  • Mitochondrial Diseases - Dormant Projects
  • Mitochondrial Diseases - Discontinued Products
  • Mitochondrial Diseases - Product Development Milestones
    • Featured News & Press Releases
      • Mar 18, 2013: St George's University Of London Receives £3.3m MRC Grant For Developing New Treatment For Rare Metabolic Disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mitochondrial Diseases, H1 2014
  • Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Mitochondrial Diseases - Pipeline by NeuroVive Pharmaceutical AB, H1 2014
  • Mitochondrial Diseases - Pipeline by Edison Pharmaceuticals, Inc., H1 2014
  • Mitochondrial Diseases - Pipeline by ElexoPharm GmbH, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Mitochondrial Diseases Therapeutics - Recent Pipeline Updates, H1 2014
  • Mitochondrial Diseases - Dormant Projects, H1 2014
  • Mitochondrial Diseases - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Mitochondrial Diseases, H1 2014
  • Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top